Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development

The MarketWatch News Department was not involved in the creation of this content.


NEW YORK, Dec. 1, 2020 /PRNewswire via COMTEX/ —
NEW YORK, Dec. 1, 2020 /PRNewswire/ — Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced the appointment of Mary Mei Chen, M.D., Ph.D. to the position of Vice President of Clinical Development, effective immediately. In this role, Dr. Chen will lead the clinical development of Actinium’s CD33 program including the Actimab-A plus CLAG-M and Actimab-A plus venetoclax combination trials in relapsed and refractory Acute Myeloid Leukemia (“R/R AML”). Dr. Chen joins Actinium from GlycoMimetics, where she played a leading role in multiple clinical trials including the global pivotal Phase 3 study of uproleselan (GMI-1271-301). In addition to working on Actimab-A development, Dr. Chen will also utilize her training in immunology and experience in translational medicine to identify areas of synergy between targeted radiotherapy with

Read More

Global Brand Strategy and Design Agency, Soulsight Chicago, Names Jessica Feld as New Senior Vice President of Brand Partnerships

CHICAGO, Nov. 20, 2020 /PRNewswire/ — Soulsight, a leading, Chicago-based brand strategy and design agency with a client roster that includes global powerhouse brands such as MolsonCoors, PepsiCo, KraftHeinz, and Nike, has promoted Jessica Feld to a brand new position, Senior Vice President of Brand Partnerships.

Jessica Feld

In her nine years of success at Soulsight, Jessica has proven herself time and time again to be a major contributor to the agency’s overall organizational growth. Jessica has led Soulsight’s expansion strategy within our CPG and Sports & entertainment verticals, that has allowed Soulsight to provide current and new partners expanded capabilities that aid in holistically bringing their business objectives to fruition with the aim of energizing their brands for consistent relevancy and impactful sales results. Jessica has shown great endurance and professional maturity in building her department from the ground up, winning countless Requests for Proposal on Soulsight’s behalf along

Read More

Elektrofi Announces Appointment of Paul Herbert as Senior Vice President of Pharmaceutical Development

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the appointment of Paul Herbert to Senior Vice President of Pharmaceutical Development.

“Paul is a seasoned leader with a significant track record of accomplishment in the life sciences industry,” said Chase Coffman, co-founder and CEO, Elektrofi. “His technical and operational experience will help us realize critical milestones, and his insights and guidance will be important to our business as we work towards the clinic next year.”

Mr. Herbert is a highly experienced senior executive with a proven track record in the pharmaceutical industry. Prior to joining Elektrofi, Mr. Herbert served as Vice President of Process Development & Engineering at Alkermes, where he led teams of up to 100 individuals in all aspects of drug product operations, including sterile process design, regulatory documentation, CDMO/CMO management, and clinical manufacturing. An industry veteran with approximately 30 years of experience

Read More

Imprivata Names Mark McArdle as Senior Vice President of Products and Design

Former executive at eSentire and McAfee takes product management and product design helm to advance digital transformation in healthcare

Mark McArdle

Senior Vice President of Products and Design at Imprivata
Senior Vice President of Products and Design at Imprivata
Senior Vice President of Products and Design at Imprivata

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) — Imprivata®, the digital identity company for healthcare, today announced the appointment of Mark McArdle to Senior Vice President of Products and Design. Mr. McArdle has more than two decades of experience in software development, Software-as-a-Service (SaaS), in Cybersecurity and advanced products for the enterprise, SMB, and consumer markets.

In his new role, Mark is responsible for leading all product management and product design activities across the Imprivata portfolio of digital identity solutions, and accelerating delivery of innovative solutions with higher value to Imprivata customers. His responsibilities align with the Imprivata digital identity framework for healthcare, a unified, security- and efficiency-focused strategy

Read More